Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of tolvaptan in autosomal dominant polycystic kidney disease (Japan)
jRCT2080221325Phase 3
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Otsuka Pharmaceutical Co., Ltd.
02
Drugs
tolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on jRCT2080221325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221325.